Connor Clark & Lunn Investment Management Ltd. Has $734,000 Position in Accuray Incorporated $ARAY

Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Accuray Incorporated (NASDAQ:ARAY) by 47.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 536,102 shares of the medical equipment provider’s stock after acquiring an additional 171,826 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Accuray were worth $734,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Nuveen LLC acquired a new stake in shares of Accuray during the 1st quarter worth $609,000. Hsbc Holdings PLC raised its stake in Accuray by 15.4% in the first quarter. Hsbc Holdings PLC now owns 122,654 shares of the medical equipment provider’s stock valued at $221,000 after purchasing an additional 16,389 shares in the last quarter. Williams & Novak LLC lifted its position in Accuray by 25.5% during the second quarter. Williams & Novak LLC now owns 68,970 shares of the medical equipment provider’s stock worth $94,000 after purchasing an additional 14,000 shares during the period. Armistice Capital LLC grew its stake in Accuray by 105.2% during the first quarter. Armistice Capital LLC now owns 2,536,000 shares of the medical equipment provider’s stock worth $4,539,000 after buying an additional 1,300,000 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in Accuray by 18,739.1% in the 1st quarter. Russell Investments Group Ltd. now owns 192,912 shares of the medical equipment provider’s stock valued at $345,000 after buying an additional 191,888 shares during the period. 64.08% of the stock is owned by institutional investors and hedge funds.

Accuray Price Performance

Shares of NASDAQ:ARAY opened at $0.97 on Wednesday. Accuray Incorporated has a one year low of $0.94 and a one year high of $2.95. The company has a debt-to-equity ratio of 1.53, a current ratio of 1.65 and a quick ratio of 0.92. The company has a market cap of $110.14 million, a price-to-earnings ratio of -48.59 and a beta of 1.39. The firm has a 50 day simple moving average of $1.53 and a 200 day simple moving average of $1.47.

Accuray (NASDAQ:ARAY) last posted its earnings results on Wednesday, November 5th. The medical equipment provider reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.13). Accuray had a negative return on equity of 4.92% and a negative net margin of 0.35%.The company had revenue of $93.94 million for the quarter, compared to the consensus estimate of $91.34 million. Accuray has set its FY 2026 guidance at EPS. Research analysts predict that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ARAY. Wall Street Zen downgraded shares of Accuray from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. BTIG Research lowered their price objective on shares of Accuray from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, November 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Accuray in a report on Thursday, November 13th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $4.00.

Accuray Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.